QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KITE stock logo

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

KITE Stock News Headlines

2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Go fly a kite ... for mental health
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
See More Headlines
Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2017
Today
4/19/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Arie S. Belldegrun
    Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson
    Chief Financial Officer
  • Cynthia M. Butitta
    Chief Operating Officer
  • David Chang M.D. Ph.D.
    Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim
    Executive Vice President - Business Development
  • Timothy L. Moore
    Executive Vice President - Technical Operations
  • Christine Cassiano
    Senior Vice President - Corporate Communications and Investor Relations

  • Bio & Compensation - 
  • Jian Irish Ph.D.
    Senior Vice President - Supply Chain

  • Bio & Compensation - 
  • Jeffrey Wiezorek M.D.
    Senior Vice President - Clinical Development
  • Shawn Cline Tomasello
    Chief Commercial Officer

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to analysts' expectations of $5.74 million. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.54) EPS.

What other stocks do shareholders of (KITE) own?
This page (NASDAQ:KITE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners